These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12736106)

  • 1. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
    Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis.
    Wu CE; Liaw CC
    Support Care Cancer; 2012 Oct; 20(10):2357-61. PubMed ID: 22187110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
    Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
    J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
    Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
    Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
    Hesketh PJ; Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
    Navari RM; Reinhardt RR; Gralla RJ; Kris MG; Hesketh PJ; Khojasteh A; Kindler H; Grote TH; Pendergrass K; Grunberg SM; Carides AD; Gertz BJ
    N Engl J Med; 1999 Jan; 340(3):190-5. PubMed ID: 9917226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiemetic drugs.
    Roila F; Fatigoni S
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
    Warr D
    Expert Opin Pharmacother; 2006 Aug; 7(12):1653-8. PubMed ID: 16872268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
    Rojas C; Li Y; Zhang J; Stathis M; Alt J; Thomas AG; Cantoreggi S; Sebastiani S; Pietra C; Slusher BS
    J Pharmacol Exp Ther; 2010 Nov; 335(2):362-8. PubMed ID: 20724484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
    Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
    Ishimaru K; Takano A; Katsura M; Yamaguchi N; Kaneko K; Takahashi H
    Asian Pac J Cancer Prev; 2014; 15(22):9627-30. PubMed ID: 25520079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.